8 results about "Amitriptyline" patented technology

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The invention discloses a novel alkaloid Oreonudine G extracted from wild poppy and an application of the novel alkaloid Oreonudine G in preparation of an antidepressant drug. The preparation method of the Oreonudine G comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, performing silica gel column chromatography on the chloroform extraction part, recrystallizing and the like to obtain the Oreonudine G. In-vitro pharmacological experiments show that the Oreonudine G can significantly inhibit reuptake of noradrenaline (NE), and the NE inhibition rate of the Oreonudine G is 43.0%, which is significantly higher than that of a positive drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The present application provides the application of amitriptyline in the treatment of acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann Pick type C.

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

The invention provides compositions and methods for administering therapeutic compounds, particularly cyclobenzaprine or amitriptyline, for absorption through the mucosa, wherein the compositions contain a basifying agent in addition to the therapeutic agent. The compositions and methods have a number of unexpected pharmacokinetic benefits over oral administration. Methods of treating fibromyalgia in a human subject are also provided.

The invention discloses a method for extracting alkaloid meconoquintupline (meconoquintupline) from wild opium poppy and application of the meconoquintupline (meconoquintupline) in preparation of an antidepressant drug. The meconopsis quintuplina alkali is prepared by the following steps: extracting the overground part of dried wild poppy by 95% ethanol, acidifying the extract, extracting by petroleum ether, adjusting the acid water layer to be alkaline by alkali liquor, extracting by chloroform, performing silica gel column chromatography on the chloroform extraction part, purifying by preparative high performance liquid chromatography, and the like, thereby obtaining the meconopsis quintuplina alkali. The meconopsis quintuplingensis alkali is obtained. Pharmacological experiments show that the meconopsis quintuplina alkali prepared by the method has a remarkable inhibition effect on reuptake of 5-hydroxytryptamine (5-HT) and noradrenaline (NE), and the inhibition rate is remarkably higher than that of a positive drug amitriptyline. The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The invention discloses a compound with remarkable noradrenaline (NE) reuptake inhibition activity and application of the compound in preparation of an anti-depression drug. The compound is a compound Oreonudine F. The preparation method of the compound comprises the following steps: extracting an overground part of wild poppy by using 95% ethanol, acidifying an extract, extracting by using petroleum ether, adjusting an acid water layer to be alkaline by using alkali liquor, and extracting by using chloroform. The chloroform extraction part is subjected to silica gel column chromatography, C18 ODS column chromatography, preparative high performance liquid chromatography separation and the like, and the compound Oreonudine F is obtained. In-vitro activity test results show that the compound Oreonudine F significantly inhibits reabsorption of NE (the inhibition rate is 45.6%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine F is superior to that of a positive control drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a polymeric micelle preparation for treating neuropsychiatric diseases as well as a preparation method and application thereof. The preparation comprises amitriptyline, scoparone, SolutolHS15 and a hydrotropy auxiliary material HPMCK4M according to a specific ratio, the particle size of the micelle prepared by adopting a self-assembly method is 10-100 nm, the solubility of amitriptyline and scoparone can be remarkably improved, the synergistic effect of amitriptyline quick release and scoparone slow release is achieved, the micelle stability is excellent, the bioavailability is high, and the bioavailability is high. The medicine is suitable for treating neuropsychiatric diseases such as depression and anxiety, and is high in safety.